ethyl ester of N-3,4-dichlorophenylalanine | 22212-58-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl ester of N-3,4-dichlorophenylalanine
• 英文别名: 2-(3,4-dichloro-phenylamino)-propionic acid ethyl ester；N-(3,4-dichlorophenyl)alanine ethyl ester；N-(3,4-Dichlorphenyl)-alanin-ethylester；N-(3.4-Dichlorphenyl)alaninethylester；ethyl 2-(3,4-dichloroanilino)propanoate
• CAS: 22212-58-4
• 化学式: C₁₁H₁₃Cl₂NO₂
• 分子量: 262.136
• InChiKey: TUFYEVMTXRPQQK-UHFFFAOYSA-N

物化性质

• 沸点：
  367.2±27.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl ester of N-3,4-dichlorophenylalanine 在 水 、 lithium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 3.0h， 以82%的产率得到N-3,4-dichlorophenylalanine
  参考文献：
  名称：

  NOVEL HETEROCYCLYL COMPOUNDS

  摘要：

  这项发明涉及式(I)的新异环烷基化合物：其中A、X、R3、R4、R5、R6、R7、R8、R9、R10、m、n和p如描述和索赔中所定义，并且其生理上可接受的盐。这些化合物是CCR2受体、CCR5受体和/或CCR3受体的拮抗剂，可用作药物。

  公开号：

  US20100022518A1
• 作为产物：
  描述：

  丙酮酸乙酯 、 3,4-二氯苯胺 生成 ethyl ester of N-3,4-dichlorophenylalanine
  参考文献：
  名称：

  N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions

  摘要：

  揭示了一种抑制β-淀粉样肽释放和/或合成的化合物，因此，对治疗阿尔茨海默病具有实用价值。还揭示了包括抑制β-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防性和治疗性治疗阿尔茨海默病的方法。

  公开号：

  US05965614A1

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：Athena Neurosciences, Inc.

  公开号：US06506782B1

  公开（公告）日：2003-01-14

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。
• Selective Rhodium-Catalyzed Reduction of Tertiary Amides in Amino Acid Esters and Peptides
  作者：Shoubhik Das、Yuehui Li、Christoph Bornschein、Sabine Pisiewicz、Konstanze Kiersch、Dirk Michalik、Fabrice Gallou、Kathrin Junge、Matthias Beller

  DOI：10.1002/anie.201503584

  日期：2015.10.12

  a variety of novel peptide derivatives for chemical biology studies and potential pharmaceutical applications. The catalytic system tolerates a variety of functional groups including secondary amides, ester, nitrile, thiomethyl, and hydroxy groups. This convenient hydrosilylation reaction proceeds at ambient conditions and is operationally safe because no air‐sensitive reagents or highly reactive metal

  描述了氨基酸衍生物和肽中叔酰胺键的有效还原。通过将可商购的铑前体和双（二苯基膦基）丙烷（dppp）配体与苯基硅烷一起用作还原剂，可以实现官能团的选择性。这种方法可以对生物学上感兴趣的肽进行特定的还原衍生，并可以直接访问各种新颖的肽衍生物，用于化学生物学研究和潜在的药物应用。催化系统可耐受各种官能团，包括仲酰胺，酯，腈，硫代甲基和羟基。这种便捷的氢化硅烷化反应可在环境条件下进行，并且操作安全，因为不需要空气敏感的试剂或高反应性的金属氢化物。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020173504A1

  公开（公告）日：2002-11-21

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及抑制&bgr;-淀粉样肽的释放和/或合成的化合物，因此具有治疗阿尔茨海默病的效用。还公开了包含抑制&bgr;-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防和治疗阿尔茨海默病的方法。
• N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
  申请人：——

  公开号：US20010020097A1

  公开（公告）日：2001-09-06

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及一种抑制β-淀粉样肽释放和/或其合成的化合物，因此在治疗阿尔茨海默病方面具有用途。还公开了包括抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这种药物组合物预防和治疗阿尔茨海默病的方法。